Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.71 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518933 | 0.94 | MTNR1A (0.64) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL5205624 | 0.93 | NPC1 (0.69) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3197659 | 0.92 | MTNR1A (0.63) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL3197669 | 0.92 | MTNR1A (0.63) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL3188745 | 0.92 | ENPP3 (0.69) | MTNR1AMTNR1BHTTNPC1RAB9A | |
| SCHEMBL8199064 | 0.89 | SMN1; SMN2 (0.64) | MTNR1AMTNR1BHTTACHEBACE1 | |
| SCHEMBL3210865 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL8595938 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL8597711 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BHTTNAMPTACHE | |
| SCHEMBL3210874 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BHTTNAMPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116250545-B | Bacillus amyloliquefaciens FCC1256 compositions and methods of controlling plant pathogens | FMC公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119950330-A | Insect repellent | FMC有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119855490-A | Method for providing control data for an application device | 巴斯夫欧洲公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024076891-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-114617136-B | Microbial compositions for promoting plant growth and treating plant diseases and methods of use | FMC有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-116456831-A | Biological insecticide | 坎纳尔地球科学有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116250545-A | Bacillus amyloliquefaciens FCC1256 compositions and methods of controlling plant pathogens | FMC公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-107426963-A | For agriculture chemistry mixture to be applied to the method and vehicle of field operating area | 巴斯夫欧洲公司 | 2017-12-01 | — | — | CN | disclosed |
| EP-2556070-B1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIV HEALTH NETWORK (CA) | 2017-06-07 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | MTNR1A 932/4885MTNR1B 908/4885HTT 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.